Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12646137 | 0.84 | MAPK1 (0.58) | MAPK1LMNACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL12984658 | 0.82 | MAPK1 (0.56) | MAPK1LMNACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL18125941 | 0.81 | MAPK1 (1.00) | MAPK1CYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL27726904 | 0.79 | MAPK1 (0.52) | MAPK1LMNACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL2823777 | 0.78 | MAPK1 (0.51) | MAPK1CYP2C19ALDH1A1HTTKDM4E | |
| SCHEMBL2827052 | 0.78 | KDM4E (0.57) | MAPK1LMNACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL2348518 | 0.78 | MAPK1 (0.47) | MAPK1LMNACYP1A2ALDH1A1TDP1 | |
| SCHEMBL13240613 | 0.78 | MAPK1 (0.51) | MAPK1LMNACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL16968020 | 0.77 | MAPK1 (0.46) | MAPK1LMNAALDH1A1TDP1L3MBTL1 | |
| SCHEMBL14547115 | 0.76 | MAPK1 (0.49) | MAPK1LMNACYP1A2CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230087342-A1 | AZEPANE DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-03-23 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022210479-A1 | USE OF AZEPANE DERIVATIVE FOR TREATMENT, AMELIORATION OR PREVENTION OF κ-OPIOID RECEPTOR-RELATED DISEASES | 日本ケミファ株式会社 | 2022-10-06 | — | — | WO | disclosed |
| EP-4039331-A1 | AZEPAN DERIVATIVE | Nippon Chemiphar Co., Ltd. (JP) | 2022-08-10 | — | — | EP | disclosed |
| CN-114761082-A | Azepane derivatives | 日本化学药品株式会社 | 2022-07-15 | — | — | CN | disclosed |
| WO-2021132524-A1 | EPOXY AZEPAN DERIVATIVE | 日本ケミファ株式会社 | 2021-07-01 | — | — | WO | disclosed |
| WO-2021065898-A1 | AZEPAN DERIVATIVE | 日本ケミファ株式会社 | 2021-04-08 | — | — | WO | disclosed |
| US-20180369213-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2018-12-27 | — | — | US | disclosed |
| EP-3122741-B1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-06-06 | — | — | EP | disclosed |
| US-9951063-B2 | 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-24 | — | — | US | disclosed |
| US-7745484-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-06-29 | — | — | US | disclosed |
| CN-101287738-A | Imidazo benzodiazepine derivatives | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | CN | disclosed |
| EP-1971598-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1937688-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| WO-2008005368-A2 | PIPERAZINES AS P2X7 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2007061670-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007042421-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369213-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CCR1, CCR3, CCR2 | MAPK1 1125/4885LMNA 4596/4885CYP1A2 3055/4885 |
| US-20230087342-A1 | AZEPANE DERIVATIVE | ADCY10, AZI2, PRMT1 | MAPK1 576/4885LMNA 4336/4885CYP1A2 105/4885 |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | MAPK1 862/4885LMNA 2852/4885CYP1A2 452/4885 |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | MAPK1 3844/4885LMNA 705/4885CYP1A2 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.